Modern approaches to non-specific dengue control in Southeast Asia
Dengue fever remains a major and rapidly growing public health challenge in Southeast Asia, accompanied by a substantial and increasing socioeconomic burden. These trends underscore the need for effective, integrated, and region-specific strategies for dengue prevention and control. This review provides a structured overview and comparative analysis of established and emerging approaches to both specific and non-specific dengue prevention. With regard to specific prophylaxis, currently licensed vaccines and vaccine candidates under development – Dengvaxia (CYD-TDV), TAK-003, and Butantan-DV are discussed, with emphasis on their efficacy across different serological profiles, age-related limitations, safety data, and regulatory status. In addition, recent advances in pre-exposure and post-exposure chemoprophylaxis are examined, including studies on riamilovir, a broad-spectrum antiviral agent active against RNA viruses. Non-specific prevention strategies addressed in this review include contemporary vector control approaches targeting Aedes aegypti and Aedes albopictus, such as chemical insecticides, biological agents (including Wolbachia and Bacillus thuringiensis israelensis), genetic modification of mosquitoes, the sterile insect technique (SIT), and the use of drones for targeted treatment of mosquito breeding sites. The role of educational and community-based interventions aimed at increasing public awareness and promoting behavioral change in endemic settings is also highlighted. By integrating perspectives from immunization, antiviral pharmacology, vector biology, and biotechnology, this review adopts an interdisciplinary approach to dengue prevention and emphasizes the practical incorporation of these strategies into existing healthcare systems. The article may be of interest to specialists in epidemiology, infectious diseases, global health, and professionals involved in the design and implementation of arboviral disease prevention programsKozlov K.V., Soloviev A.I., Maltsev O.V., Brianskaya-Kasianenko K.V., Peredelsky E.V., Blyumkin D.B., Solovieva P.A., Novitsky A.A., Luong Thi Mo.
Keywords
dengue fever
prevention
vaccine
mosquitoes
antiviral agents
vectors
References
1. World Health Organization. Disease outbreak news: Dengue outbreak in Southeast Asia. Published November 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON498
2. Shepard D.S., Undurraga E.A., Halasa Y.A. Economic and disease burden of dengue in Southeast Asia. PLoS Negl. Trop. Dis. 2013; 7(2): e2055. DOI: 10.1371/journal.pntd.0002055
3. Biswal S., Reynales H., Saez-Llorens X., Lopez P., Borja-Tabora C., Kosalaraksa P. et al. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents. N. Engl. J. Med. 2019; 381(21): 2009–2019. DOI: 10.1056/NEJMoa1903869
4. World Health Organization. Dengue and severe dengue. WHO Fact Sheets, 2022. https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue.
5. Khobragade A.W., Kadam D.D. Efficacy of tetravalent dengue vaccine: a systematic review and meta-analysis. Indian J. Community Med. 2021; 46(2): 191–194. DOI: 10.4103/ijcm.IJCM_608_20
6. Tricou V., Yu D., Reynales H., Biswal S., Saez-Llorens X., Sirivichayakul C. et al. Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4.5-year results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Glob. Health. 2024; 12(2): e257–e270. DOI: 10.1016/S2214-109X(23)00522-3
7. Fernando L., Kastner R., Wickramasinghe P., Fernando A.D., Gunasekera D., Nguyen V.H. et al. Role of the dengue vaccine TAK-003 in an outbreak response: modeling the Sri Lanka experience. PLoS Negl. Trop. Dis. 2024; 18(8): e0012376. DOI: 10.1371/journal.pntd.0012376
8. Nogueira M.L., Cintra M.A.T., Moreira J.A., Patiño E.G., Braga P.E., Tenório J.C.V. et al. Efficacy and safety of Butantan-DV in participants aged 2–59 years through an extended follow-up: results from a double-blind, randomised, placebo-controlled, phase 3, multicentre trial in Brazil. Lancet Infect. Dis. 2024; 24(11): 1234–1244. DOI: 10.1016/S1473-3099(24)00376-1
9. Khan M.B., Yang Z.S., Lin C.Y., Hsu M.C., Urbina A.N., Assavalapsakul W. et al. Dengue overview: an updated systemic review. J. Infect. Public Health. 2023; 16(10): 1625–1642. DOI: 10.1016/j.jiph.2023.08.001
10. Weeratunga P., Rodrigo C., Fernando S.D., Rajapakse S. Control methods for Aedes albopictus and Aedes aegypti. Cochrane Database Syst. Rev. 2017; 2017(8): CD012759. DOI: 10.1002/14651858.CD012759
11. Kamgang B., Acântara J., Tedjou A., Keumeni C., Yougang A., Ancia A. et al. Entomological surveys and insecticide susceptibility profile of Aedes aegypti during the dengue outbreak in Sao Tome and Principe in 2022. PLoS Negl. Trop. Dis. 2024; 18(6): e0011903. DOI: 10.1371/journal.pntd.0011903
12. Kongkaew C., Sakunrag I., Chaiyakunapruk N., Tawatsin A. Effectiveness of citronella preparations in preventing mosquito bites: systematic review of controlled laboratory experimental studies. Trop. Med. Int. Health. 2011; 16(7): 802–810. DOI: 10.1111/j.1365-3156.2011.02781.x
13. Most B., Pommier de Santi V., Pagès F., Mura M., Uedelhoven W.M., Faulde M.K. Long-lasting permethrin-impregnated clothing: protective efficacy against malaria in hyperendemic foci, and laundering, wearing, and weathering effects on residual bioactivity after worst-case use in the rain forests of French Guiana. Parasitol. Res. 2017; 116(2): 677–684. DOI: 10.1007/s00436-016-5333-6
14. Hossain M.J., Das M., Islam M.W., Shahjahan M., Ferdous J. Community engagement and social participation in dengue prevention: a cross-sectional study in Dhaka City. Health Sci. Rep. 2024; 7(4): e2022. DOI: 10.1002/hsr2.2022
15. Brown H., McGraw E.A. Wolbachia and mosquito vector control. Lancet Infect. Dis. 2018; 18(7): 663–671. DOI: 10.1016/S1473-3099(18)30143-0
16. Carvalho D.O., McKemey A.R., Garziera L., Lacroix R., Donnelly C.A., Alphey L. et al. Suppression of a field population of Aedes aegypti in Brazil by sustained release of transgenic male mosquitoes. PLoS Negl. Trop. Dis. 2015; 9(7): e0003864. DOI: 10.1371/journal.pntd.0003864
17. Ritchie S.A., Rapley L.P., Benjamin S. Bacillus thuringiensis var. israelensis (Bti) provides residual control of Aedes aegypti in small containers. Am. J. Trop. Med. Hyg. 2010; 82(6): 1053–1059. DOI: 10.4269/ajtmh.2010.09-0603
18. Carvalho K.D.S., Crespo M.M., Araújo A.P., da Silva R.S., de Melo-Santos M.A.V., de Oliveira C.M.F. et al. Long-term exposure of Aedes aegypti to Bacillus thuringiensis svar. israelensis did not involve altered susceptibility to this microbial larvicide or to other control agents. Parasit. Vectors 2018; 11(1): 673. DOI: 10.1186/s13071-018-3246-1
19. Ranathunge T., Harishchandra J., Maiga H., Bouyer J., Gunawardena Y.I.N.S., Hapugoda M. Development of the sterile insect technique to control the dengue vector Aedes aegypti (Linnaeus) in Sri Lanka. PLoS One 2022; 17(4): e0265244. DOI: 10.1371/journal.pone.0265244
20. Nazni W.A., Teoh G.-N., Nuradila M.A., Shaikh Ismail S.N.H., Tanusshni M., Muhammad Arif M.A. et al. Impact of sterile Aedes aegypti males releases on vector dynamics: insights from Malaysian field trials. Infect. Dis. Poverty. 2025; 14: 33. DOI: 10.1186/s40249-025-01303-x
21. Carrasco-Escobar G., Moreno M., Fornace K., Herrera-Varela M., Manrique E., Conn J.E. The use of drones for mosquito surveillance and control. Parasit. Vectors 2022; 15: 473. DOI: 10.1186/s13071-022-05580-5
22. Chang J., Schul W., Butters T.D., Yip A., Liu B., Goh A. et al. Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Antiviral Res. 2011; 89(1): 26–34. DOI: 10.1016/j.antiviral.2010.11.002
23. Malinoski F.J., Hasty S.E., Ussery M.A., Dalrymple J.M. Prophylactic ribavirin treatment of dengue type 1 infection in rhesus monkeys. Antiviral. Res. 1990; 13(3): 139–149. DOI: 10.1016/0166-3542(90)90029-7
24. Сабитов А.У., Сорокин П.В., Дашутина С.Ю. Эффективность и безопасность применения препарата риамиловир в лечении пациентов с COVID-19. Антибиотики и химиотерапия 2021; 66(1–2): 35–37. [Sabitov A.U., Sorokin P.V., Dashutina C.Yu. Effectiveness and safety of the Riavimovir drug in the treatment of COVID-19 patients. Antibiotics and Chemotherapy 2021; 66(1–2): 35–37. (In Russ.)]. DOI: 10.37489/0235-2990-2021-66-1-2-33-37
25. Козлов К.В., Мальцев О.В., Касьяненко К.В., Сукачев В.С., Саулевич А.В., Карякин С.С. и др. Оценка профилактической эффективности нуклеозидного аналога риамиловира в отношении ОРВИ у лиц из организованного коллектива. Терапевтический архив. 2024; 96(11): 1035–1041. [Kozlov K.V., Maltsev O.V., Kasyanenko K.V., Sukachev V.S., Saulevich A.V., Karyakin S.S. et al. Effectiveness of riamilovir in preventing respiratory viral infection among young people from organized collectives. Therapeutic Archive 2024; 96(11): 1035–1041. (In Russ.)]. DOI: 10.26442/00403660.2024.11.203024
26. Жданов К.В., Мальцев О.В., Касьяненко К.В., Козлов К.В., Сукачев В.С., Львов Н.И. и др. Новые подходы к этиотропной терапии пациентов с ОРВИ препаратом риамиловир. Антибиотики и химиотерапия 2023; 68(9–10): 63–71. [Zhdanov K.V., Maltsev О.V., Kasyanenko K.V., Kozlov K.V., Sukachev V.S., Lvov N.I. et al. New Approaches to Etiotropic Therapy of ARVI Patients with Riamilovir. Antibiotics and Chemotherapy 2023; 68(9–10): 63–71. (In Russ.)]. DOI: 10.37489/0235-2990-2023-68-9-10-63-71
27. Мальцев О.В., Касьяненко К.В., Жданов К.В., Малышев Н.А., Коломоец Е.В., Коному В.К. Опыт применения противовирусного препарата риамиловир у пациента с лихорадкой денге в Гвинейской Республике (клинический случай). Терапевтический архив. 2023; 95(1): 85–89. [Maltsev O.V., Kasyanenko K.V., Zhdanov K.V., Malyshev N.A., Kolomoets E.V., Konomou V.K. The experience in treatment of dengue fever using antiviral drug riamilovir in the Republic of Guinea (case report). Therapeutic Archive 2023; 95(1): 85–89. (In Russ.)]. DOI: 10.26442/00403660.2023.01.202054
28. Пшеничная Н.Ю., Лужецкая А.А., Коннова Ю.А., Лизенфельд И.А., Цветкова Н.А., Жданов К.В. Опыт лечения тяжелой лихорадки денге препаратом риамиловир. Инфекционные болезни. 2024; 22(2): 133–136. [Pshenichnaya N.Yu., Luzhetskaya A.A., Konnova Yu.A., Lizinfeld I.A., Tsvetkova N.A., Zhdanov K.V. Experience in the treatment of severe dengue fever with riamilovir. Infectious Diseases 2024; 22(2): 133–136. (In Russ.)]. DOI: 10.20953/1729-9225-2024-2-133-136
29. Мальцев О.В., Козлов К.В., Дамбаев И.С., Брянская-Касьяненко К.В., Новицкий А.А., Соловьёва П.А. Использование новых подходов к комплексной терапии лихорадки денге. Инфекционные болезни. 2025; 23(2): 90–98. [Maltsev O.V., Kozlov K.V., Dambaev I.S., Brianskaya-Kasyanenko K.V., Novitsky A.A., Solovieva P.A. New approaches to comprehensive therapy of Dengue fever. Infectious Diseases 2025; 23(2): 90–98. (In Russ.)]. DOI: 10.20953/1729-9225-2025-2-90-98
About the Authors
Professor; Konstantin V. Kozlov, МD, Head, Department of Infectious Diseases with a course in medical parasitology and tropical diseases, Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; kosttiak@mail.ru; https://orcid.org/0000-0002-4398-7525Alexey I. Solovyov, МD, Associate Professor, Head, Academician E.N. Pavlovsky Department of Biology, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; solopiter@gmail.com; https://orcid.org/0000-0002-3731-1756
Oleg V. Maltsev, Cand. Med. Sci., Associate Professor, Department of Infectious Diseases with a course in medical parasitology and tropical diseases, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; olegdzein-m@yandex.ru; https://orcid.org/0000-0002-6286-9946
Kristina V. Brianskaia-Kasianenko, Cand. Med. Sci., Lecturer, Department of Infectious Diseases with a course in medical parasitology and tropical diseases, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; dr.snegur@gmail.com; https://orcid.org/0000-0001-9294-7346
Evgeny V. Peredelsky, Cand. Med. Sci., Senior Lecturer, Department of Infectious Diseases with a course in medical parasitology and tropical diseases, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; peredelskiy@yandex.ru; https://orcid.org/0000-0001-6638-1203
Dzhordzh B. Blyumkin, Lecturer, Department of Biology named after Academician E.N. Pavlovsky, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; blumbiology@yandex ru; https://orcid.org/0009-0006-8094-8222
Polina A. Solovyova, Resident Physician, Department of Infectious Diseases with a course in medical parasitology and tropical diseases, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; solopiterpolina@gmail.com; https://orcid.org/0009-0000-9753-8322
Aleksandr A. Novitsky, Postgraduate Student (Adjunct), Department of Infectious Diseases with a course in medical parasitology and tropical diseases, S.M. Kirov Military Medical Academy, Ministry of Defense of the Russian Federation, Saint Petersburg, Russia; alex.novitsky2011@yandex.ru; https://orcid.org/0009-0001-9419-519X
Luong Thi Mo, Cand. Chem. Sci., Head, Tropical Medicine Laboratory, Joint Russian–Vietnamese Tropical Research and Technology Center, Ho Chi Minh City, Socialist Republic of Vietnam; luongmo@vrtc.org.vn; https://orcid.org/0000-0002-6035-5933
Similar Articles
